more about the case](https://www.businesswire.com/news/home/20220318005586/en/Kirby-McInerney-LLP-Reminds-Investors-that-a-Class-Action-Lawsuit-Has-Been-Filed-Against-BioVie-Inc-and-Encourages-Investors-to-Contact-the-Firm-BIVI).
The lawsuit alleges that BioVie and certain of its executives made false and misleading statements and/or failed to disclose that: (i) the Company’s trial of BIV201 in patients suffering from advanced alcoholic hepatitis was not designed with an appropriate control group; (ii) the Company’s positive statements about the efficacy and safety of BIV201 in treating alcoholic hepatitis were not supported by reliable data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you acquired BioVie securities during the Class Period and would like to discuss this lawsuit or your legal rights, please contact us by visiting our website or contacting Joshua Rubin, Esq. at (888) 579-8640 or [email protected].
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Source link